stockrow
Saturday 7 November 2026
Export ACRS’s income statement to Excel — free account
Aclaris Therapeutics, Inc.
ACRS Healthcare Biotechnology
Aclaris Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.8 million, down 58.2% from fiscal 2024.
- Revenue
- −55.1%
- EPS
- 0.00%
- Free cash flow
- −119.9%
Quarter to September 2026, against a year earlier
3.88
0.27
+7.48%
Follow ACRS
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 3 | 6 | 5 | 5 | 2 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z-Score |
(5.60) | (5.49) | (5.25) | 7.00 | 5.59 | (6.55) | (7.74) | 0.60 | 22.06 | — |
P/S ratio |
47.14 | 10.24 | 2.35 | 33.03 | 122.00 | 42.46 | 18.51 | 37.28 | 0.00 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Altman Z″-Score (non-manufacturers) |
(18.21) | (12.36) | (8.69) | (2.07) | (1.53) | (22.93) | (15.95) | 1.84 | 14.38 | — |
P/Operating CF |
(28.10) | (21.45) | (10.84) | (51.41) | (48.31) | (31.07) | (3.84) | (10.51) | (38.63) | — |
Beneish M-Score |
(2.97) | 58.37 | (1.93) | (0.88) | (3.27) | (3.29) | (0.01) | (0.97) | — | — |
P/B ratio |
3.58 | 1.23 | 0.47 | 4.97 | 4.18 | 7.31 | 1.12 | 1.33 | 3.12 | — |
Price to Tangible BV |
3.84 | 1.29 | 0.49 | 5.15 | 4.33 | 9.02 | 1.25 | 1.51 | 3.53 | — |
EV/Sales |
36.92 | 4.75 | (1.12) | 26.08 | 95.28 | 35.75 | 1.61 | 19.31 | 0.00 | — |
EV/EBITDA |
0.00 | 0.00 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(6.13) | (4.43) | 0.45 | (11.48) | (12.36) | (6.00) | (0.07) | (1.47) | (9.32) | — |
EV/FCF |
(6.12) | (4.40) | 0.44 | (11.38) | (12.28) | (5.93) | (0.07) | (1.45) | (9.12) | — |
Quick Ratio |
3.36 | 3.99 | 3.86 | 9.94 | 8.37 | 3.69 | 3.38 | 6.16 | 15.23 | 22.05 |
Current Ratio |
3.36 | 3.99 | 4.16 | 10.55 | 8.94 | 3.87 | 3.74 | 6.57 | 15.69 | 22.27 |
Net Debt/EBITDA |
1.20 | 0.80 | 1.23 | 2.44 | 2.16 | 0.88 | 0.83 | 1.67 | 3.59 | 2.83 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 15.05% | 3.63% | 10.86% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.28 | 0.05 | 0.14 | 0.00 | 0.00 |
Asset Turnover |
0.04 | 0.09 | 0.14 | 0.12 | 0.04 | 0.08 | 0.02 | 0.02 | 0.01 | 0.00 |
Operating CF/Net income |
0.73 | 0.15 | 0.89 | 0.78 | 0.57 | 0.76 | 0.60 | 0.76 | 0.80 | 0.72 |
Capex/Depreciation |
(0.24) | (44.52) | (1.52) | (0.76) | (0.33) | (0.34) | (0.06) | (0.72) | (3.07) | (1.93) |
| (50.20%) | (84.46%) | (49.88%) | (44.01%) | (77.34%) | (94.86%) | (113.22%) | (60.28%) | (34.72%) | (36.70%) | |
| (34.10%) | (63.23%) | (39.15%) | (34.36%) | (56.44%) | (60.34%) | (86.32%) | (51.14%) | (32.66%) | (35.59%) | |
ROIC |
(387.11%) | (211.41%) | (159.82%) | 0.00% | (946.13%) | 0.00% | 0.00% | (68.76%) | (108.19%) | (94.07%) |
Return on Tangible Assets |
(94.87%) | (138.49%) | (88.90%) | (41.25%) | (49.53%) | (115.23%) | (252.74%) | (85.95%) | (36.14%) | (36.20%) |
Average Days of Receivables |
259.55 | 240.94 | 3.48 | 5.94 | 33.63 | 43.47 | 60.79 | 33.41 | 104.32 | — |
Research and Development Expense of Revenue |
672.69% | 179.41% | 314.84% | 261.54% | 648.03% | 452.61% | 1,517.98% | 989.12% | 2,127.39% | 0.00% |
Selling, General and Administrative Expense of Revenue |
280.76% | 118.61% | 103.72% | 84.47% | 349.34% | 316.72% | 658.32% | 418.81% | 1,130.90% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.03 | 0.03 | 0.10 | 0.07 | 0.09 | 0.11 | 0.00 |
Share Based Compensation of Revenue |
158.24% | 57.99% | 65.74% | 50.55% | 207.96% | 172.89% | 382.71% | 326.04% | 857.40% | 0.00% |
Graham Net Nets |
0.11 | 0.32 | 1.21 | 0.18 | 0.18 | 0.09 | 0.71 | 0.42 | 0.26 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(17.61%) | (60.89%) | (120.95%) | (8.83%) | (11.21%) | (18.55%) | (206.88%) | (54.67%) | (9.63%) | — |
Free Cash Flow Yield |
(12.80%) | (10.54%) | (108.64%) | (6.94%) | (6.36%) | (14.20%) | (125.30%) | (35.67%) | (7.95%) | — |
Revenue per Share |
0.06 | 0.24 | 0.45 | 0.46 | 0.12 | 0.15 | 0.10 | 0.19 | 0.06 | 0.00 |
Operating CF per Share |
(0.38) | (0.26) | (1.12) | (1.04) | (0.92) | (0.91) | (2.33) | (3.06) | (1.95) | (1.62) |
Capex per Share |
0.00 | (0.46) | (0.02) | (0.01) | (0.01) | (0.01) | (0.04) | (0.04) | (0.04) | (0.01) |
Free Cash Flow per Share |
(0.39) | (0.72) | (1.14) | (1.05) | (0.92) | (0.92) | (2.37) | (3.10) | (1.99) | (1.63) |
Cash per Share |
0.74 | 1.47 | 1.71 | 3.34 | 3.37 | 1.27 | 1.82 | 5.10 | 6.90 | 6.41 |
Shareholders Equity per Share |
0.84 | 2.01 | 2.25 | 3.03 | 3.48 | 0.89 | 1.69 | 6.54 | 8.02 | 7.91 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.84 | 2.01 | 2.25 | 3.03 | 3.48 | 0.89 | 1.69 | 6.54 | 8.02 | 7.91 |
Free Cash Flow |
(47.22) | (56.01) | (79.63) | (68.17) | (52.44) | (39.09) | (98.06) | (102.17) | (55.90) | (34.83) |
Working Capital |
67.67 | 94.36 | 97.90 | 209.61 | 182.10 | 42.62 | 61.37 | 152.16 | 187.46 | 132.33 |
Capital Expenditures |
(0.11) | (35.93) | (1.31) | (0.60) | (0.31) | (0.45) | (1.61) | (1.36) | (1.23) | (0.23) |
Net Current Asset Value |
38.94 | 61.18 | 88.63 | 174.58 | 151.16 | 24.36 | 55.42 | 119.06 | 181.97 | 131.96 |
EV/EBIT |
0.00 | 0.00 | 0.36 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.01 | 1.92 | 0.04 | 0.02 | 0.05 | 0.07 | 0.38 | 0.22 | 0.73 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.60 | 0.80 | 0.53 | 0.73 | 0.69 | 0.80 | 10.09 | 0.82 | 0.19 | 0.25 |
Cash ROIC |
(24.36%) | (20.81%) | (28.82%) | (16.42%) | (13.49%) | (38.16%) | (66.03%) | (24.74%) | (13.34%) | (11.36%) |
Accounts Receivable Turnover |
0.87 | 2.96 | 79.92 | 53.75 | 9.69 | 8.78 | 6.67 | 11.78 | 3.22 | — |
Accounts Payable Turnover |
0.82 | 2.28 | 1.88 | 1.18 | 0.62 | 0.68 | 0.38 | 0.44 | 0.23 | 0.07 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.47 | 12.25 | 0.00 | 0.00 |
Average Days of Payables |
659.35 | 110.74 | 179.22 | 315.90 | 773.29 | 373.60 | 892.65 | 984.38 | 2,365.39 | 8,653.54 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
8.96 | 6.33 | 0.39 | 0.55 | 0.70 | 0.74 | 0.63 | 0.52 | 0.52 | — |
Average Payables |
8.92 | 6.78 | 9.61 | 10.17 | 7.62 | 7.59 | 10.80 | 9.75 | 5.33 | 1.83 |
Average Inventory |
— | — | — | — | — | — | 0.35 | 0.35 | — | — |
Average Assets |
190.39 | 208.87 | 226.00 | 252.90 | 161.00 | 84.54 | 186.93 | 259.54 | 209.80 | 135.08 |
Average Common Equity |
129.32 | 156.37 | 177.40 | 197.48 | 117.50 | 53.78 | 142.52 | 220.19 | 197.38 | 131.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026